These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 18671886

  • 21. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.
    Sasaki R, Narisawa-Saito M, Yugawa T, Fujita M, Tashiro H, Katabuchi H, Kiyono T.
    Carcinogenesis; 2009 Mar; 30(3):423-31. PubMed ID: 19126650
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The mutational profile of sporadic epithelial ovarian carcinoma.
    Kalamanathan S, Bates V, Lord R, Green JA.
    Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
    [Abstract] [Full Text] [Related]

  • 26. [Pathologic features of BRCA-associated ovarian carcinoma].
    Guo DH, Zheng WX.
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):846-50. PubMed ID: 24507111
    [No Abstract] [Full Text] [Related]

  • 27. [Clinical significance of two-tier grading system of ovarian serous carcinoma].
    Zhang J, Guo XQ, Liu JS.
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):739-41. PubMed ID: 22321346
    [No Abstract] [Full Text] [Related]

  • 28. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis.
    Herrington CS, McCluggage WG.
    J Pathol; 2010 Jan; 220(1):5-6. PubMed ID: 19882674
    [Abstract] [Full Text] [Related]

  • 29. Geographical variations in TP53 mutational spectrum in ovarian carcinomas.
    Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjańczyk J.
    Ann Hum Genet; 2006 Sep; 70(Pt 5):594-604. PubMed ID: 16907706
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [Abstract] [Full Text] [Related]

  • 32. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
    Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S, Jimenez-Linan M, Karlan BY, Gentry-Maharaj A, Menon U, Polo SH, Candido Dos Reis FJ, Doherty JA, Gayther SA, Sharma R, Larson MC, Harnett PR, Hatfield E, de Andrade JM, Nelson GS, Steed H, Schildkraut JM, Carney ME, Høgdall E, Whittemore AS, Widschwendter M, Kennedy CJ, Wang F, Wang Q, Wang C, Armasu SM, Daley F, Coulson P, Jones ME, Anglesio MS, Chow C, de Fazio A, García-Closas M, Brucker SY, Cybulski C, Harris HR, Hartkopf AD, Huzarski T, Jensen A, Lubiński J, Oszurek O, Benitez J, Mina F, Staebler A, Taran FA, Pasternak J, Talhouk A, Rossing MA, Hendley J, AOCS GroupPeter MacCallum Cancer Center, Melbourne, VIC, Australia.Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Edwards RP, Fereday S, Modugno F, Ness RB, Sieh W, El-Bahrawy MA, Winham SJ, Lester J, Kjaer SK, Gronwald J, Sinn P, Fasching PA, Chang-Claude J, Moysich KB, Bowtell DD, Hernandez BY, Luk H, Behrens S, Shah M, Jung A, Ghatage P, Alsop J, Alsop K, García-Donas J, Thompson PJ, Swerdlow AJ, Karpinskyj C, Cazorla-Jiménez A, García MJ, Deen S, Wilkens LR, Palacios J, Berchuck A, Koziak JM, Brenton JD, Cook LS, Goode EL, Huntsman DG, Ramus SJ, Köbel M.
    J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
    [Abstract] [Full Text] [Related]

  • 33. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma.
    Miller K, Price JH, Dobbs SP, McClelland RH, Kennedy K, McCluggage WG.
    J Clin Pathol; 2008 May; 61(5):652-7. PubMed ID: 18006668
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
    Wang X, Wei Z, Gao F, Zhang X, Zhou C, Zhu F, Wang Q, Gao Q, Ma C, Sun W, Kong B, Zhang L.
    Anticancer Res; 2008 May; 28(5B):2991-6. PubMed ID: 19031945
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas].
    Shen Y, Yang F, Liu JS.
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
    Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P.
    Cancer Biol Ther; 2020 Aug; 21(3):197-202. PubMed ID: 31709901
    [Abstract] [Full Text] [Related]

  • 40. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.
    Piek JM, Kenemans P, Verheijen RH.
    Am J Obstet Gynecol; 2004 Sep; 191(3):718-32. PubMed ID: 15467531
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.